Tobacco Use CessationNCT03209557
Pilot Trial of Using SmokeBeat to Monitor and Increase Smoking Abstinence in Pregnant Women
A study testing SmartWatch SmokeBeat Application in people with Tobacco Use Cessation and Pregnancy Related, run by University of Pennsylvania at 1 site in United States.
Trial summary
Investigators will assess the feasibility of implementing a randomized control trial of a behavioral intervention that uses smartwatch technology to monitor smoking behavior with texts aimed at reducing smoking in pregnant women who smoke. Read more about this study
- Who is it for?
- Any age, women onlyHealthy volunteers can take part
- Conditions the study is for
- Tobacco Use Cessation, Pregnancy Related
- What is being tested?
- SmartWatch SmokeBeat Application
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Jul 2017to 30 Apr 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Pregnant or within 3 weeks postpartum
- Self-reported smoking
- Part of the Nurse Family Partnership or Healthy Beginnings
- Uses an Android smart phone
Who cannot join
- Does not speak English
- Not interested in wearing a smart watch for 12 weeks
Trial locations and contacts
1 site in 1 country.
United States1 site
Lancaster General Hospital
Lancaster, Pennsylvania, 17602
About this study
Official title: Pilot Trial Testing Feasibility and Effectiveness of Using SmokeBeat to Monitor and Increase Smoking Abstinence in Pregnant Women
Investigators will assess the feasibility of implementing a randomized control trial of a behavioral intervention that uses smartwatch technology to monitor smoking behavior with texts aimed at reducing smoking in pregnant women who smoke. Investigators will compare the cessation rate of pregnant women who receive usual care through programs aimed at reducing smoking with pregnant women who receive usual care and are using the SmokeBeat app with a smartwatch.
Read the detailed description
Somatix, LGH, and the Center for Health Incentives and Behavioral Economics of the University of Pennsylvania (CHIBE) will collaborate in using the unique smoking recognition technology of SmokeBeat app to track and analyze the smoking habits of LGH target smoking population. The target population for the SmokeBeat pilot is low-income pregnant women who smoke. This will enable us to gain insights on this target population and reach higher effectiveness of smoking cessation. Each participant will be enrolled in the trial for 12 weeks. Women randomized to the intervention arm will be given an Asus Zenwatch 2 smartwatch and a smartphone data plan for the duration of the study. Women assigned to the control group will be given the same smartwatch to keep following their participation in the trial. The tentative start date is June 2017.
After completing the consent participants will be randomized to one of two study arms. The control arm will consist of 25 pregnant women. Each will be provided with usual care through Healthy Beginnings or NFP but will not receive a smartwatch or the active intervention. Smoking behavior will be measured by self-report and sample testing for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly and will be identical to the intervention group. Following their completion of this trial they will receive a smartwatch as well. The intervention arm will consist of 25 pregnant women. Each will be enrolled and provided with a smartwatch. The SmokeBeat app will be active. Smoking behavior will be measured by the smartwatch for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly. All participants assigned to the intervention arm will be allowed to keep the smartwatch for their participation and be provided with a smartphone data plan for the duration of the study.
Two types of tests will be conducted with each participant, regardless of self-reported quit status. NicAlert strip tests (semi quantitative test) will be used to test saliva cotinine during weeks 2, 3, 5, 6, 8, 9, 11, and 12 of the participant's participation. This test will provide us with an accurate indicator of whether or not women have quit smoking while reducing the cost of the pilot study. A quantitative liquid chromatography cotinine test conducted by ARUP Labs will be used to test urine during weeks 1, 4, 7, and 10 for all women regardless of self-reported and smartwatch smoking status. This test, while more expensive, will provide us with the concentration of cotinine for each participant. This number can be directly compared to the self-reported and smartwatch reported number of cigarettes smoked as a way to validate self-report and smartwatch accuracy even when a participant has not quit smoking completely.
The main research instruments will consist of questionnaires on a subjects smoking habits and psychological tests that will help evaluate which types of patients are most able to quit smoking. All participants will be asked to complete an intake questionnaire at baseline (estimated length 15 minutes) and an exit questionnaire at the end of study participation 3 months after they start in the program (estimated length 15 minutes). Investigators will examine whether baseline values and/or changes during 3 months in these variables confound, causally mediate, or modify the effects of the intervention on quit rates. (a) Standard questionnaires will be administered to collect the following information: demographics (age, gender, ethnicity, marital status, and education), number of years of smoking, number of prior quit attempts, duration of previous abstinence periods, and current smoking rate. Nicotine dependence will be measured by the modified Fagerström Test for Nicotine Dependence (FTND), a 6-item measure of nicotine dependence. The FTND has satisfactory internal consistency (Cronbachs alpha=0.64) and high test-retest reliability (r=0.88).3 Heavy smokers are at highest risk for smoking related illnesses. Some but not all studies suggest that heavier smokers have lower quit rates. Investigators will evaluate whether FTND score either confounds or modifies the effects of the intervention. (b) Investigators will measure smoker's baseline readiness to quit using the Prochaska Stage of Change. (c) Investigators will assess participant's types and locations of jobs and whether they are exposed to smoking at home or in the workplace. (d) Participants use, durations, and doses of nicotine replacement therapy, varenicline, and buproprion will be assessed throughout the study. Participants will be asked to not use Nicotine patches or gum during the course of the study so that it will not interfere with weekly testing for smoking abstinence. (e) Time (or delay) discounting. Time discounting (known interchangeably as present-biased preferences or delay discounting) is a measure of impulsivity that reflects people's tendencies to discount the value of a reward as a function of how far in the future it would be received. People who smoke and use other drugs have steeper delayed discounting functions, meaning they have stronger present biased preferences. This is expected because smoking, like other unhealthy behaviors, entails immediate gratifications in exchange for future health problems. This also suggests that provision of early rewards, such as payments, might more effectively promote smoking cessation than interventions focusing on future rewards such as long-term health benefits, and that this effect might be strongest among those with the steepest discounting functions. Consistent with prior work, investigators will use a 7-item monetary choice questionnaire that defines ranges of delayed discounting by fitting a hyperbolic function to participants expressed preferences for smaller immediate versus larger delayed rewards. Information will also be collected weekly from participants on withdrawal and craving for nicotine as well as self-reported number of cigarettes per week. Investigators will also administer a 5 question weekly survey that addresses weekly levels of cravings, stress, social support, and asks about current cigarette use. All questions will be rated on a Likert scale, except for the number of cigarettes smoked, that will be an estimate of use.
The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. Investigators will be able to create the types of messaging they want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/.
A second pilot were begun in the summer of 2018. Intervention participants were offered a monetary reward for each day they went without smoking. Control participants were offered a financial incentive to wear the watch. In the fall of 2018 a third will start with an increase in the financial incentive, and a new smart band model.
A third pilot was started in the winter of 2018/2019. New participants were recruited, who were then randomized to one of two arms. Both arms were given smartbands that tracked their smoking use. Participants in the control arm were offered financial incentives for every day that they consistently wore the smartband. Participants in the experimental arm were offered financial incentives for consistently wearing the smartband and abstaining from smoking. All participants completed remote nicotine testing and survey questionnaires with study personnel via video chat. Five weekly video chats are scheduled with participants.
- Conditions
- Tobacco Use Cessation, Pregnancy Related
- Being tested
- SmartWatch SmokeBeat Application
- Keywords
- Mobile Technology, Sociobehavioral
- Medical subject headings
- Tobacco Use Cessation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SmartWatch SmokeBeat ApplicationOther
The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. We will be able to create the types of messaging we want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | 25 pregnant women will be enrolled and provided with usual care through Healthy Beginnings or NFP but will not receive a smartwatch or the active intervention. Smoking behavior will be measured by self-report and sample testing for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly and will be identical to the intervention group. They will be compensated for sample collection and survey completion. |
| SmokeBeat Intervention | Experimental | 25 pregnant women will be enrolled and provided with a smartwatch. The smartwatch SmokeBeat application will be active. Smoking behavior will be measured by the smartwatch for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly.
A second phase of the trial was initiated to evaluate a new watch. The smoking habits of participants who are receiving financial incentives to wear the watch are being compared to participants who are being given financial incentives for every day they go without smoking.
A third phase of the trial was initiated to evaluate efficacy of larger financial incentives. All participants are incentivized to wear the watch, with the experimental arm also incentivized to abstain from smoking. Receives: Other: SmartWatch SmokeBeat Application |
What is being measured
The primary outcome is the main question the study is designed to answer.
Smoking cessation rate biochemical verification
Quit rates in control vs. intervention group as determined by weekly cotinine testing.
Measured: 12 weeks
Smoking cessation rate smartwatch
Quit rates in control vs. intervention group as measured by the smartwatch.
Measured: 12 weeks
Secondary outcomes (8)
Desire to quit
We will compare the self-reported desire to quit before and after the study and compare across groups.
Measured: 12 weeks
Usability of the smartwatch and application
We will measure through self-report the usability participants experience while using the SmokeBeat application and smartwatch.
Measured: 12 weeks
Usability of the smartwatch and application
We will measure through qualitative interviews the usability participants experience while using the SmokeBeat application and smartwatch.
Measured: 12 weeks
Likability of the smartwatch and application
We will measure through self-report the likability participants experience while using the SmokeBeat application and smartwatch.
Measured: 12 weeks
Likability of the smartwatch and application
We will measure through qualitative interviews the likability participants experience while using the SmokeBeat application and smartwatch.
Measured: 12 weeks
Number of cigarettes smoked self-report
Number of cigarettes smoked in control vs. intervention group as measured by self-report.
Measured: 12 weeks
Number of cigarettes smoked measured by smartwatch
Number of cigarettes smoked in control vs. intervention group as measured by the smartwatch.
Measured: 12 weeks
Smoking cessation rate self-report
Quit rates in control vs. intervention group as measured by self-report.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2017
- Study start5 Jul 2017
- Primary completion30 Apr 2019
- Study completion30 Apr 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for Tobacco Use CessationStudies of the same condition, open and under way.
- More trials run by University of PennsylvaniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Pennsylvania
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alison Buttenheim, University of Pennsylvania
- Investigators
- Alison Buttenheim, PhD, MBA, Principal investigator, University of Pennsylvania
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03209557
- Sponsor's protocol ID
- 827096
- Status last verified
- May 2019
- First submitted
- 14 Jun 2017
- Last updated
- 9 May 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Each participant will have a unique identifier to protect their confidentiality. Only pre-specified research coordinators will have access to identifiable participant information for contacting participants for follow-up. Only authorized personnel will have access to the data which will be maintained on encrypted hard-drives and destroyed after 7 years.
Publications
McCallum DM, Fosson GH, Pisu M. Making the case for medicaid funding of smoking cessation treatment programs: an application to state-level health care savings. J Health Care Poor Underserved. 2014 Nov;25(4):1922-40. doi: 10.1353/hpu.2014.0171.
PubMed 25418250Centers for Disease Control and Prevention (CDC). The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services; 2004. U.S. Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004
Salihu HM, Aliyu MH, Pierre-Louis BJ, Alexander GR. Levels of excess infant deaths attributable to maternal smoking during pregnancy in the United States. Matern Child Health J. 2003 Dec;7(4):219-27. doi: 10.1023/a:1027319517405.
PubMed 14682499Pregnancy Risk Assessment Monitoring System (PRAMS) and Smoking, Data from 2000-2011. http://www.cdc.gov/prams/pramstat/index.html
Adams EK, Melvin CL, Raskind-Hood C, Joski PJ, Galactionova E. Infant delivery costs related to maternal smoking: an update. Nicotine Tob Res. 2011 Aug;13(8):627-37. doi: 10.1093/ntr/ntr042. Epub 2011 Jul 20.
PubMed 21778148Kornhauser M, Schneiderman R. How plans can improve outcomes and cut costs for preterm infant care. Manag Care. 2010 Jan;19(1):28-30. No abstract available.
PubMed 20131638Lumley J, Chamberlain C, Dowswell T, Oliver S, Oakley L, Watson L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD001055. doi: 10.1002/14651858.CD001055.pub3.
PubMed 19588322Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119-27. doi: 10.1111/j.1360-0443.1991.tb01879.x.
PubMed 1932883Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983 Jun;51(3):390-5. doi: 10.1037//0022-006x.51.3.390. No abstract available.
PubMed 6863699Prochaska JO, DiClemente CC, Norcross JC. In search of how people change. Applications to addictive behaviors. Am Psychol. 1992 Sep;47(9):1102-14. doi: 10.1037//0003-066x.47.9.1102.
PubMed 1329589Weber EU, Johnson EJ, Milch KF, Chang H, Brodscholl JC, Goldstein DG. Asymmetric discounting in intertemporal choice: a query-theory account. Psychol Sci. 2007 Jun;18(6):516-23. doi: 10.1111/j.1467-9280.2007.01932.x.
PubMed 17576265Joyce CM, Saulsgiver K, Mohanty S, Bachireddy C, Molfetta C, Steffy M, Yoder A, Buttenheim AM. Remote Patient Monitoring and Incentives to Support Smoking Cessation Among Pregnant and Postpartum Medicaid Members: Three Randomized Controlled Pilot Studies. JMIR Form Res. 2021 Sep 30;5(9):e27801. doi: 10.2196/27801.
PubMed 34591023
Study at a glance
From the registry record, last updated by the sponsor on 9 May 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Trial Testing Feasibility and Effectiveness of Using SmokeBeat to Monitor and Increase Smoking Abstinence in Pregnant Women
- ClinicalTrials.gov ID
- NCT03209557
- Acronym / sponsor ID
- 827096
- Conditions
- Tobacco Use Cessation, Pregnancy Related
- Keywords
- Mobile Technology, Sociobehavioral
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- University of PennsylvaniaUniversity, hospital or other
- Study start
- 5 Jul 2017 (actual)
- Primary completion
- 30 Apr 2019 (actual)
- Study completion
- 30 Apr 2019 (actual)
- First posted
- 6 Jul 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Investigators will assess the feasibility of implementing a randomized control trial of a behavioral intervention that uses smartwatch technology to monitor smoking behavior with texts aimed at reducing smoking in pregnant women who smoke. Investigators will compare the cessation rate of pregnant women who receive usual care through programs aimed at reducing smoking with pregnant women who receive usual care and are using the SmokeBeat app with a smartwatch.
Detailed description
Somatix, LGH, and the Center for Health Incentives and Behavioral Economics of the University of Pennsylvania (CHIBE) will collaborate in using the unique smoking recognition technology of SmokeBeat app to track and analyze the smoking habits of LGH target smoking population. The target population for the SmokeBeat pilot is low-income pregnant women who smoke. This will enable us to gain insights on this target population and reach higher effectiveness of smoking cessation. Each participant will be enrolled in the trial for 12 weeks. Women randomized to the intervention arm will be given an Asus Zenwatch 2 smartwatch and a smartphone data plan for the duration of the study. Women assigned to the control group will be given the same smartwatch to keep following their participation in the trial. The tentative start date is June 2017.
After completing the consent participants will be randomized to one of two study arms. The control arm will consist of 25 pregnant women. Each will be provided with usual care through Healthy Beginnings or NFP but will not receive a smartwatch or the active intervention. Smoking behavior will be measured by self-report and sample testing for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly and will be identical to the intervention group. Following their completion of this trial they will receive a smartwatch as well. The intervention arm will consist of 25 pregnant women. Each will be enrolled and provided with a smartwatch. The SmokeBeat app will be active. Smoking behavior will be measured by the smartwatch for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly. All participants assigned to the intervention arm will be allowed to keep the smartwatch for their participation and be provided with a smartphone data plan for the duration of the study.
Two types of tests will be conducted with each participant, regardless of self-reported quit status. NicAlert strip tests (semi quantitative test) will be used to test saliva cotinine during weeks 2, 3, 5, 6, 8, 9, 11, and 12 of the participant's participation. This test will provide us with an accurate indicator of whether or not women have quit smoking while reducing the cost of the pilot study. A quantitative liquid chromatography cotinine test conducted by ARUP Labs will be used to test urine during weeks 1, 4, 7, and 10 for all women regardless of self-reported and smartwatch smoking status. This test, while more expensive, will provide us with the concentration of cotinine for each participant. This number can be directly compared to the self-reported and smartwatch reported number of cigarettes smoked as a way to validate self-report and smartwatch accuracy even when a participant has not quit smoking completely.
The main research instruments will consist of questionnaires on a subjects smoking habits and psychological tests that will help evaluate which types of patients are most able to quit smoking. All participants will be asked to complete an intake questionnaire at baseline (estimated length 15 minutes) and an exit questionnaire at the end of study participation 3 months after they start in the program (estimated length 15 minutes). Investigators will examine whether baseline values and/or changes during 3 months in these variables confound, causally mediate, or modify the effects of the intervention on quit rates. (a) Standard questionnaires will be administered to collect the following information: demographics (age, gender, ethnicity, marital status, and education), number of years of smoking, number of prior quit attempts, duration of previous abstinence periods, and current smoking rate. Nicotine dependence will be measured by the modified Fagerström Test for Nicotine Dependence (FTND), a 6-item measure of nicotine dependence. The FTND has satisfactory internal consistency (Cronbachs alpha=0.64) and high test-retest reliability (r=0.88).3 Heavy smokers are at highest risk for smoking related illnesses. Some but not all studies suggest that heavier smokers have lower quit rates. Investigators will evaluate whether FTND score either confounds or modifies the effects of the intervention. (b) Investigators will measure smoker's baseline readiness to quit using the Prochaska Stage of Change. (c) Investigators will assess participant's types and locations of jobs and whether they are exposed to smoking at home or in the workplace. (d) Participants use, durations, and doses of nicotine replacement therapy, varenicline, and buproprion will be assessed throughout the study. Participants will be asked to not use Nicotine patches or gum during the course of the study so that it will not interfere with weekly testing for smoking abstinence. (e) Time (or delay) discounting. Time discounting (known interchangeably as present-biased preferences or delay discounting) is a measure of impulsivity that reflects people's tendencies to discount the value of a reward as a function of how far in the future it would be received. People who smoke and use other drugs have steeper delayed discounting functions, meaning they have stronger present biased preferences. This is expected because smoking, like other unhealthy behaviors, entails immediate gratifications in exchange for future health problems. This also suggests that provision of early rewards, such as payments, might more effectively promote smoking cessation than interventions focusing on future rewards such as long-term health benefits, and that this effect might be strongest among those with the steepest discounting functions. Consistent with prior work, investigators will use a 7-item monetary choice questionnaire that defines ranges of delayed discounting by fitting a hyperbolic function to participants expressed preferences for smaller immediate versus larger delayed rewards. Information will also be collected weekly from participants on withdrawal and craving for nicotine as well as self-reported number of cigarettes per week. Investigators will also administer a 5 question weekly survey that addresses weekly levels of cravings, stress, social support, and asks about current cigarette use. All questions will be rated on a Likert scale, except for the number of cigarettes smoked, that will be an estimate of use.
The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. Investigators will be able to create the types of messaging they want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/.
A second pilot were begun in the summer of 2018. Intervention participants were offered a monetary reward for each day they went without smoking. Control participants were offered a financial incentive to wear the watch. In the fall of 2018 a third will start with an increase in the financial incentive, and a new smart band model.
A third pilot was started in the winter of 2018/2019. New participants were recruited, who were then randomized to one of two arms. Both arms were given smartbands that tracked their smoking use. Participants in the control arm were offered financial incentives for every day that they consistently wore the smartband. Participants in the experimental arm were offered financial incentives for consistently wearing the smartband and abstaining from smoking. All participants completed remote nicotine testing and survey questionnaires with study personnel via video chat. Five weekly video chats are scheduled with participants.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –25 pregnant women will be enrolled and provided with usual care through Healthy Beginnings or NFP but will not receive a smartwatch or the active intervention. Smoking behavior will be measured by self-report and sample testing for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly and will be identical to the intervention group. They will be compensated for sample collection and survey completion. |
| SmokeBeat Intervention | Experimental | Other: SmartWatch SmokeBeat Application25 pregnant women will be enrolled and provided with a smartwatch. The smartwatch SmokeBeat application will be active. Smoking behavior will be measured by the smartwatch for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly. A second phase of the trial was initiated to evaluate a new watch. The smoking habits of participants who are receiving financial incentives to wear the watch are being compared to participants who are being given financial incentives for every day they go without smoking. A third phase of the trial was initiated to evaluate efficacy of larger financial incentives. All participants are incentivized to wear the watch, with the experimental arm also incentivized to abstain from smoking. |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Pregnant or within 3 weeks postpartum
- Self-reported smoking
- Part of the Nurse Family Partnership or Healthy Beginnings
- Uses an Android smart phone
Key exclusion criteria (2 listed)
- Does not speak English
- Not interested in wearing a smart watch for 12 weeks
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SmartWatch SmokeBeat ApplicationThe SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. We will be able to create the types of messaging we want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/ | Other | SmokeBeat Intervention |
Primary outcome
Smoking cessation rate biochemical verification
Time frame: 12 weeks
Quit rates in control vs. intervention group as determined by weekly cotinine testing.
Smoking cessation rate smartwatch
Time frame: 12 weeks
Quit rates in control vs. intervention group as measured by the smartwatch.
8 secondary outcomes
Desire to quit
Time frame: 12 weeks
Usability of the smartwatch and application
Time frame: 12 weeks
Usability of the smartwatch and application
Time frame: 12 weeks
Likability of the smartwatch and application
Time frame: 12 weeks
Likability of the smartwatch and application
Time frame: 12 weeks
Number of cigarettes smoked self-report
Time frame: 12 weeks
Number of cigarettes smoked measured by smartwatch
Time frame: 12 weeks
Smoking cessation rate self-report
Time frame: 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 May 2019.
- Background: PubMed 25418250McCallum DM, Fosson GH, Pisu M. Making the case for medicaid funding of smoking cessation treatment programs: an application to state-level health care savings. J Health Care Poor Underserved. 2014 Nov;25(4):1922-40. doi: 10.1353/hpu.2014.0171.
- Results publicationCenters for Disease Control and Prevention (CDC). The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services; 2004. U.S. Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004
- Results publication: PubMed 14682499Salihu HM, Aliyu MH, Pierre-Louis BJ, Alexander GR. Levels of excess infant deaths attributable to maternal smoking during pregnancy in the United States. Matern Child Health J. 2003 Dec;7(4):219-27. doi: 10.1023/a:1027319517405.
- Results publicationPregnancy Risk Assessment Monitoring System (PRAMS) and Smoking, Data from 2000-2011. http://www.cdc.gov/prams/pramstat/index.html
- Results publication: PubMed 21778148Adams EK, Melvin CL, Raskind-Hood C, Joski PJ, Galactionova E. Infant delivery costs related to maternal smoking: an update. Nicotine Tob Res. 2011 Aug;13(8):627-37. doi: 10.1093/ntr/ntr042. Epub 2011 Jul 20.
- Results publication: PubMed 20131638Kornhauser M, Schneiderman R. How plans can improve outcomes and cut costs for preterm infant care. Manag Care. 2010 Jan;19(1):28-30. No abstract available.
- Results publication: PubMed 19588322Lumley J, Chamberlain C, Dowswell T, Oliver S, Oakley L, Watson L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD001055. doi: 10.1002/14651858.CD001055.pub3.
- Results publication: PubMed 1932883Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119-27. doi: 10.1111/j.1360-0443.1991.tb01879.x.
- Results publication: PubMed 6863699Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983 Jun;51(3):390-5. doi: 10.1037//0022-006x.51.3.390. No abstract available.
- Results publication: PubMed 1329589Prochaska JO, DiClemente CC, Norcross JC. In search of how people change. Applications to addictive behaviors. Am Psychol. 1992 Sep;47(9):1102-14. doi: 10.1037//0003-066x.47.9.1102.
- Results publication: PubMed 17576265Weber EU, Johnson EJ, Milch KF, Chang H, Brodscholl JC, Goldstein DG. Asymmetric discounting in intertemporal choice: a query-theory account. Psychol Sci. 2007 Jun;18(6):516-23. doi: 10.1111/j.1467-9280.2007.01932.x.
- Derived from this study: PubMed 34591023Joyce CM, Saulsgiver K, Mohanty S, Bachireddy C, Molfetta C, Steffy M, Yoder A, Buttenheim AM. Remote Patient Monitoring and Incentives to Support Smoking Cessation Among Pregnant and Postpartum Medicaid Members: Three Randomized Controlled Pilot Studies. JMIR Form Res. 2021 Sep 30;5(9):e27801. doi: 10.2196/27801.
- Individual participant dataSharing planned: Yes. Each participant will have a unique identifier to protect their confidentiality. Only pre-specified research coordinators will have access to identifiable participant information for contacting participants for follow-up. Only authorized personnel will have access to the data which will be maintained on encrypted hard-drives and destroyed after 7 years.
Related trials for Tobacco Use Cessation
Not yet recruitingObservational study
PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Smoking Cessation, Lung Cancer Screening
Not yet recruiting
Impacto 2.0: Mobile Smoking Cessation Across Texas
Cigarette Smoking, Smoking Cessation
Active, not recruiting
Vaping Cessation Using the Ottawa Model for Smoking Cessation Among E-Cigarette Users
Tobacco Smoking, Vaping
Recruiting
Young Adult Tobacco/Nicotine and Cannabis Co-use
Tobacco Use Disorder, Nicotine Dependence
Recruiting
Social Media Support Groups for Adolescent Vaping Cessation
Vaping, Vaping Cessation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alison Buttenheim, PhD, MBA principal investigator
University of Pennsylvania
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SmartWatch SmokeBeat Application in people with Tobacco Use Cessation and Pregnancy Related, run by University of Pennsylvania at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 May 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Smoking cessation rate biochemical verification (time frame: 12 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03209557, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2019.